Abstract
Understanding of the mechanisms of transplant and xenotransplant rejection represents one of the most important aspects of both basic and clinical immunology. This review discusses the roles of 1) immune response and 2) the influence of various products of arachidonic acid metabolism on immune response in graft survival. The review also includes an overview of novel therapeutic approaches developed to prevent, or at least delay, graft rejection. New discoveries in basic and clinical immunology have generated new areas of research in pharmacology that may prevent rejection more efficiently, a key issue in modern medicine.
Keywords: Xenotransplant, transplant, graft rejection, immune response, hyperacute transplant rejection, acute transplant rejection, chronic transplant rejection, arachidonic acid metabolism
Current Pharmaceutical Design
Title: New Frontiers in the Therapeutic Management of Transplant Rejection
Volume: 12 Issue: 19
Author(s): Juan B. De Sanctis, Jenny V. Garmendia, Anna Radzioch and Danuta Radzioch
Affiliation:
Keywords: Xenotransplant, transplant, graft rejection, immune response, hyperacute transplant rejection, acute transplant rejection, chronic transplant rejection, arachidonic acid metabolism
Abstract: Understanding of the mechanisms of transplant and xenotransplant rejection represents one of the most important aspects of both basic and clinical immunology. This review discusses the roles of 1) immune response and 2) the influence of various products of arachidonic acid metabolism on immune response in graft survival. The review also includes an overview of novel therapeutic approaches developed to prevent, or at least delay, graft rejection. New discoveries in basic and clinical immunology have generated new areas of research in pharmacology that may prevent rejection more efficiently, a key issue in modern medicine.
Export Options
About this article
Cite this article as:
De Sanctis B. Juan, Garmendia V. Jenny, Radzioch Anna and Radzioch Danuta, New Frontiers in the Therapeutic Management of Transplant Rejection, Current Pharmaceutical Design 2006; 12 (19) . https://dx.doi.org/10.2174/138161206777698990
DOI https://dx.doi.org/10.2174/138161206777698990 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Uses of the Plants Belonging to the Genus <i>Commiphora</i>
Cardiovascular & Hematological Agents in Medicinal Chemistry Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction
Current Pharmaceutical Design Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Targeting Mitochondria for Cardiac Protection
Current Drug Targets Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease
Current Neurovascular Research Opposite Effects of Two-Derived Antioxidants from Physalis pubescens L. on Hepatocellular Carcinoma Cell Line Malhavu
Current Pharmaceutical Biotechnology Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology